If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...

Analyst Graham Parry of Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), retaining the ...

ScaleReadytm, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReadytm, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has ...

The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual ...

why we're daunted by the commercial challenge of launching all ... The FDA in June expanded the use of GSK's Arexvy vaccine in adults between the ages of 50 and 59. The U.S. Centers for Disease ...